Venous thromboembolism in hospitalized patients receiving chemotherapy for malignancies at Japanese community hospital: prospective observational study

Table 4 Multivariable analysis of risk factors for total VTE of 29 patients and newly developed VTE of 12 patients (n = 97)

	Total VTE			Newly developed VTE
Variable	OR	(95% CI)	P	OR	(95% CI)	P
Elderly female^a	3.3	(0.9–12.4)	0.066		-
BMI ≥25^b		-		2.5	(0.5–12.0)	0.25
Reduced mobility^c	4.9	(1.0–24.9)	0.057		-
6–12 months from tumor onset^d		-		3.0	(0.6–15.8)	0.19
Increased TAT^e	2.4	(0.9–6.4)^f	0.092	3.8	(0.7–20.8)^g	0.12
Non-increased PIC^h	1.2	(0.3–4.0)	0.78		-
Increased TAT^e and non-increased PIC^h	3.0	(1.1–8.2)ⁱ	0.034^*	9.4	(1.7–51.9)^j	0.011^*

Abbreviations are as in Table 2. VIF variance inflation factor
^* P < 0.05. ^a ≥ 70 yr. vs. male and female <70 yr., adjusted for reduced mobility and non-increased PIC with increased TAT (VIF, 1.0). ^bAdjusted for 6–12 months from tumor onset, and non-increased PIC with increased TAT (VIF, 1.0). ^cAdjusted for elderly female and non-increased PIC with increased TAT (VIF, 1.0). ^dAdjusted for BMI ≥25 and non-increased PIC with increased TAT (VIF, 1.1). ^e ≥ 2.1 ng/mL. ^fAdjusted for elderly female and non-increased PIC (VIF, 1.1). ^gAdjusted for BMI ≥25 and 6–12 months from tumor onset (VIF, 1.1). ^h < 1.8 ng/mL, adjusted for elderly female and increased TAT (VIF, 1.2). ⁱAdjusted for elderly female and reduced mobility (VIF, 1.0). ^jAdjusted for BMI ≥25 and 6–12 months from tumor onset (VIF, 1.1)

ISSN: 1471-2407